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Abstract: In this study, data from breast MRI-guided near infrared 
spectroscopy (NIRS) exams delivered to 44 patients scheduled for surgical 
resection (ending in 16 benign and 28 malignant diagnoses) were analyzed 
using a spatial sensitivity metric to quantify the adequacy of the optical 
measurements for interrogating the tumor region of interest, as derived from 
the concurrent MRI scan. Along with positional sensitivity, the 
incorporation of spectral priors and the selection of an appropriate 
regularization parameter in the image reconstruction were considered, and 
found to influence the diagnostic accuracy of the recovered images. Once 
optimized, the MRI/NIRS data was able to differentiate the malignant from 
benign lesions through both total hemoglobin (p = 0.0037) and tissue 
optical index (p = 0.00019), but required the relative spatial sensitivity of 
the optical measurement data to each lesion to be above 1%. Spectral 
constraints implemented during the reconstruction were required to obtain 
statistically significant diagnostic information from images of H2O, lipids, 
and Tissue Optical Index (TOI). These results confirm the need for optical 
systems that have homogenous spatial coverage of the breast while still 
being able to accommodate the normal range of breast sizes. 
©2014 Optical Society of America 
OCIS codes: (170.0110) Imaging systems; (170.6960) Tomography; (100.6890) Three-
dimensional image processing. 
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1. Introduction 
Breast cancer is a complex and diverse disease that is routinely screened using x-ray 
mammography, which has an overall sensitivity and specificity reported to be in the mid-70s 
and high-90s, respectively, (e.g. in a relatively recent randomized multi-center trial [1]), 
although sensitivity has been found to be as low as 40% in some large trials [2]. 
Unfortunately, its effectiveness in women with mammographically dense breasts is reduced, 
especially sensitivity, which drops into the 60% range (as low as 36% in [2]). Clinically, MRI 
is the most sensitive exam for cancer surveillance, especially in the dense breast [3–9], and 
national guidelines now recommend routine breast MR screening in women with an elevated 
lifetime breast cancer risk of 20% or more [10,11]. Thus, even with pressures from healthcare 
cost containment, the emergence of x-ray tomographic systems [12–14], and the relative 
expense of an exam, the number of breast MR studies can be expected to grow in the future 
because of the exquisite soft-tissue delineation that is provided. However, breast MRI has a 
substantial false positive rate [15,16] due to its reliance on gadolinium (Gd) as a non-specific 
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contrast agent. The number of false positives caused by the technique is particularly troubling 
because of the clinical management burden that is created by the increase in contrast-
enhancing foci that need to be evaluated. As a result, supplementing the diagnostic 
information derived from MR would have significant clinical impact, especially if the 
adjunctive data were coregistered with the MR image volume and could be seamlessly 
acquired during the same procedure. 
Combined MRI/optical imaging is an emerging multi-modality technology [17–20] that 
could benefit the diagnoses of patients called back after screening for further testing or 
women at high-risk initially screened with MRI by adding functional information about the 
molecular status of the breast [21] through the optical technique which non-invasively 
quantifies oxy- and deoxy-hemoglobin (HbO and Hb), water and lipid content, and scattering 
parameters in adipose and fibroglandular tissues. To date, evidence for the potential promise 
of MRI/optical imaging has mostly been limited to anecdotal case studies [18,22], and the 
approach remains largely untested in a patient population of any size. As a result, important 
methodological issues specific to human imaging that are related to the non-linear sensitivity 
of diffuse optical methods have not been studied. For example, optical imaging is well known 
to lack sensitivity to 1) deeper lesions, 2) lesions distant from measurement locations, or 3) 
lesions that are small in size, but the quality of the data and associated images that can be 
acquired clinically is not as well understood because of the relatively limited testing on 
humans, especially when the technique is augmented with priors from another imaging 
modality, in this case, MRI. 
Our MRI/optical imaging has been under development for several years [23–26], and was 
deployed to evaluate the sensitivity of the data that can be routinely acquired during a clinical 
breast exam. Specifically, we generated a sensitivity map before image reconstruction to 
minimize over-interpretation of lesions with low sensitivity to the data collected, and 
identified criteria for data inclusion based on breast exam data acquired from a cohort of 44 
women with breast abnormalities. To the best of our knowledge, no other method exists to 
quantify, objectively, if and when the optical measurement data can be expected to recover 
accurate information about a particular lesion or region of interest in MRI/optical breast 
imaging. Non-linear image reconstruction includes both spatial and spectral constraints that 
can be incorporated at multiple stages. A regularization parameter must also be selected to 
maintain image stability while not over damping image contrast. These issues are investigated 
using the clinical data as a vehicle for determining the choices that lead to improved 
diagnostic outcomes with the combined MRI/optical imaging technique. 
2. Methods 
2.1 Instrumentation 
The MRI/optical system deployed in this study consists of six intensity modulated laser 
diodes and three continuous-wave laser diodes with wavelengths spanning from 660nm to 
850nm, and 900nm to 950nm, respectively. Sixteen sequential source positions illuminate the 
breast through a custom optical switch. During each individual source illumination, the 
remaining 15 fibers detect transmitted light with photomultiplier tubes, PMTs (Hamamatsu, 
9305-03), and large active area photodiodes (Hamamatsu C10439-03). The amplitude and 
phase (when available) of the detected light are separated by lock-in detection. The optical 
imaging hardware is located in the MR console room, and 12m fiber bundles with 4mm 
working optical diameters are passed through a custom penetration panel to enter the MR 
scanner room. These fibers are coupled into a clinical breast coil for simultaneous MR and 
optical imaging of patients or phantoms. Clinical MRI image quality and acquisition time are 
not affected by the addition of the optical fiber array. More details on the imaging 
instrumentation can be found in previous publications [25]. 
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2.2 Image reconstruction 
Breast images are processed and reconstructed with the open source software platform, 
Nirfast [27]. Briefly, the difference between measured data and a diffusion-based model of 
light propagation through the medium is minimized to yield estimates of the optical properties 
of the tissue of interest. The diffusion equation has been well studied in this setting and is an 
acceptable approximation in tissues where scattering (μs’) dominates absorption (μa), and 
source-detector separation is greater than one scattering distance [28]. In an unconstrained 
spectral reconstruction, the image formation algorithm is non-linear and solved with a 
Newton-type minimization method where the mismatch between the data and the model at 
one wavelength is minimized by changing μa and μs’. All wavelengths are reconstructed 
separately for the absorption and scattering coefficients which are then combined linearly to 
form the relevant chromophore concentrations. From these we derive Total Hemoglobin 
(HbT), Oxygen Saturation (StO2), and Tissue Optical Index (TOI) through 
HbT HbO Hb= + , 2 /StO HbO HbT= , and ( * ) /TOI HbT water lipid= . Similarly, 
scattering amplitude, A, and scattering power, b, are fit in each region to an empirically 
derived power law approximation to Mie Theory, ' bs aμ λ
−=  [29,30]. 
Constrained spectral reconstruction employs spectral priors by solving for chromophores 
directly and simultaneously based on measurements of absorption and scatter [31,32]. The 
approach is faster and more robust to noise, and previous work has indicated accuracy 
improvements occur in the recovered chromophore concentrations when the method is 
applied. However, the effect of reconstruction type (constrained vs. unconstrained) has not 
been evaluated in a large data set of patient exams, especially in the setting of also using 
spatial priors. In this study, each patient was reconstructed with both constrained and 
unconstrained spectral algorithms to assess the value of the constrained approach. The 
resulting images were evaluated relative to the known surgical pathology and expected 
physiological conditions. Two-tailed student t-tests (significance p<0.05) were performed on 
the ratio of mean tumor to mean background levels of each chromophore. Given that each 
data set was used for only one test, we did not correct for multiple comparisons. 
2.3 Sensitivity analysis 
The Jacobian matrix in the image reconstruction process contains the spatial sensitivity of 
each measurement at each location within the image volume and can be used to quantify the 
overall sensitivity field of the measured data prior to image formation. The sensitivity of the 
measurements to a given region identified by MRI, Sr, can be calculated using the equation, 
[ ]log( )rS sum J r= ⋅ . Here, r is a logical vector that identifies points within the region of 
interest and J is the Jacobian. The total sensitivity of the measurements to the domain, St, is 
obtained when r is entirely true. Regions are identified by MRI during image segmentation, 
and the sensitivity of the region relative to the total sensitivity can be found by Sr/St. Relative 
tumor sensitivity is a quantity that could predict reconstructed image quality by providing a 
quantitative metric of the overlap between the measurement sensitivity and the region of 
interest. Figure 1 shows a visual example of the Jacobian-calculated sensitivity in relation to 
the tumor location. 
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Fig. 1. The Jacobian field is plotted within the MRI image volume of 3 different breasts with 
lesions (found by MRI) shown in blue. The overlap between the lesion and the Jacobian yields 
the sensitivity of the optical measurements to the lesion. These examples illustrate two cases 
(a,b) with good and one case with very poor sensitivity (c). 
Similarly to finding the sensitivity of each region, quantifying the sensitivity of each 
measurement to each region is also possible. The sensitivity of the ith measurement to region 
r, Si,r, can be calculated as [ ]log( ( ,:) )iS sum J i r= ⋅  where i selects the corresponding row of 
J, and r identifies the ROI. When this expression is applied to a given measurement, the 
sensitivity of the corresponding data to the lesion is found. Examples of optical measurements 
that possess high and low sensitivity to a lesion are illustrated in Fig. 2. 
Sensitivity analysis was applied to a data set consisting of 44 combined breast MR/optical 
breast exams to evaluate its influence on the reconstructed results. The relative sensitivity to 
each lesion was calculated as described in Section 2.3.1 and subject exams were sorted by 
lesions being the most to the least sensitive to the optical data. Reconstructed chromophore 
concentrations were compared versus the gold standard of surgical pathology in patient exams 
with high lesion sensitivity, moderate lesion sensitivity, and low lesion sensitivity to assess 
the impact of the measurement sensitivity on the diagnostic performance of the optical 
imaging results. Here, the Jacobian calculation was used to estimate a quantitative measure of 
the relative sensitivity of the data to the tumor region as described in Section 2.3.1, which was 
applied as the basis for data inclusion. 
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Fig. 2. Sensitivity of two measurements from two different breasts is illustrated. Measurements 
with high sensitivity to the tumor region (a,b) will directly impact the recovered properties of 
the tumor while other measurements will have much less influence (c,d). 
2.4 Regularization parameters 
Since the matrix to be inverted is ill-conditioned, the image formation algorithm (Eq. (1) was 
stabilized through a modified Tikhonov regularization routine. A single scalar parameter, λ, 
and identity matrix, I, make the matrix more diagonally dominant and dampens the effect of 
noise in the data. The model-data misfit, δ, is minimized to obtain the physiological 
parameters, c. 
 ( )T TJ J I c Jλ δ+ Δ = Δ  (1) 
Specifically, a modified Levenberg-Marquardt scheme regularized the amplitude and 
phase components separately, and was scaled by the maximum of the diagonal of the Hessian 
matrix between iterations. The reconstruction was stopped when the change between 
successive iterations was less than 0.2%, allowing the image reconstruction to converge 
slowly but robustly [33]. 
Three different regularization settings were evaluated in the constrained spectral 
reconstructions. Image results from each regularization were compared against relative tumor 
sensitivity, surgical pathology, and normal tissue properties to investigate the influence of 
regularization parameters on the clinical data. 
2.5 Human Subject Imaging 
Our imaging protocol for human subject examination was approved by the Committee for the 
Protection of Human Subjects at Dartmouth-Hitchcock Medical Center and Xijing Hospital. 
Written consent was obtained during which the nature of the procedure was fully explained to 
each volunteer. Each subject’s breast was positioned into a triangular interface in the prone 
position on the MR exam table and the fiber optic cables were brought into contact with the 
breast surface. In cases of smaller breast sizes, all fibers were not in contact with the skin 
surface because of curvature, and data from these channels were not incorporated into the 
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image reconstruction. The interface involved mild compression similarly to MR biopsy plates 
but maintained patient comfort during the imaging procedure. Co-registration between optical 
and MR images was accomplished through MR fiducial markers placed in the plane of each 
set of fibers, and MR images were acquired with the slice-direction in the axial geometry. 
Optical and MR data were collected concurrently with data acquisition requiring 15 and 30 
minutes, respectively. The core dynamic contrast enhanced MRI scan was a 3D, fast, low-
angle shot T1 sequence acquired in the transverse plane (6.9/2.8 [repetition time msec/echo 
time msec], flip angle of 150°) with a total of six acquisitions – one before and five after 
intravenous injection of MR contrast (0.5 mmol/ml, Gadodiamide, Omniscan, GE Healthcare) 
at 3ml. Each volume consisted of 144 slices (1mm thickness) with a matrix size of 448 x 300 
and field of view of 250-350mm depending on breast size. The resulting voxel size was 0.7 x 
0.7 x 1mm and temporal resolution was 90sec. Because data collection from the two imaging 
modalities does not interfere, optical data was typically acquired twice per subject as time 
permitted. The first data set was used for analysis. 
3. Results 
3.1 Sensitivity analysis 
The effects of spatial sensitivity were analyzed first by calculating the relative sensitivity to 
each lesion for each exam. The relative sensitivity of each lesion in malignant and benign 
groups is summarized in Fig. 3. The group of patients with a cancer diagnosis (n = 28) 
yielded a mean tumor sensitivity of 3.5% whereas the group with benign diagnoses (n = 16) 
showed a slightly lower mean of 3.3%, although no statistical difference (p = 0.86) was found 
between two groups, indicating that the measurements were not significantly different in 
terms of their sensitivity to malignant versus benign lesions. 
 
Fig. 3. Relative tumor sensitivity for malignant (n = 28) and benign (n = 16) lesions according 
to surgical pathology, showing no statistical difference between them in this estimate of 
sensitivity in the clinical data. Box ends show 25th and 75th percentile and two data sets with 
non-overlapping intervals are significantly different. 
Measurement sensitivity had a large effect on recovery of tumor chromophore 
concentrations in the malignant versus benign cases. The subject exams were sorted from the 
most to least sensitive, and reconstructed chromophore concentrations were compared to 
surgical pathology in lesions with descending sensitivity. P-values for differentiating 
malignant from benign lesions based on total hemoglobin concentration (HbT), scattering 
amplitude (SA) and Tissue Optical Index (TOI) [21] as a function of relative tumor sensitivity 
to the measurement data are presented in Fig. 4. P-values from TOI were significant (p<0.05) 
when relative tumor sensitivity was above 1.2%, and TOI was maximally significant above a 
relative tumor sensitivity of 2.5% (p = 0.00019). Total hemoglobin (HbT) was also a 
significant indicator when sensitivities above 1.2% were included. These benign and 
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malignant groups were maximally different when imaging exams with sensitivity above 2.5% 
were included (p = 0.0037). Scatter amplitude was nearly significant when the tumor 
sensitivity was above 1.2% (p = 0.09). 
 
Fig. 4. P-values for differentiating malignant from benign lesions in recovered chromophores 
(HbT, SA, TOI) are plotted as a function of relative lesion sensitivity. Number of patients 
included in the analysis (right axes) for a given relative lesion sensitivity is indicated by the 
solid (black) line. As the number of patients included in the analysis increases, the associated 
p-values decrease until approximately 1% sensitivity. 
3.2 Reconstruction type 
After sorting the patient exam data by lesion sensitivity, p-values for separating malignant 
from benign abnormalities were compared for constrained and unconstrained spectral 
reconstructions in Fig. 5. In the constrained spectral reconstructions, the p values from TOI 
and HbT exhibited significance (p<0.05) when lesion sensitivity was greater than 1.2% 
whereas only HbT and SA were significant predictors of malignancy in the unconstrained 
spectral reconstructions. HbT achieved statistical significance for lesion sensitivity above 
0.5% while SA was significant through nearly the entire sensitivity range. HbT was 
maximally significant above 1% sensitivity (p = 0.015) whereas SA was maximally 
significant above 1.3% sensitivity (p = 0.012). 
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Fig. 5. P-values for differentiating malignant from benign lesions in recovered chromophores 
are plotted as a function of relative lesion sensitivity (left axes) for constrained and 
unconstrained spectral reconstructions. Number of patients included in the analysis (right axes) 
for a given relative lesion sensitivity is indicated by the solid (black) line. Unconstrained 
reconstructions separate malignant from benign lesions in more patients in HbT and SA. 
3.3 Regularization parameters 
To investigate the effects of regularization, constrained spectral reconstructions were 
performed on all patients with three different starting regularization parameters (1, 0.1, and 
0.01) in Fig. 6. These values were selected after varying the initial regularization from 0.001 
to 1.0 in two representative cases – one malignant and one benign – and concluding that 
regularizations much above unity smoothed the lesion-to-background contrast excessively 
(i.e. nearly to unity) and below 0.01 led to unstable results. 
 
Fig. 6. The p-values of malignant versus benign groups in recovered chromophores HbT and 
SA are plotted versus relative tumor sensitivity (left axes) for three different regularizations in 
constrained spectral reconstructions. Also shown is the number of patients included (right 
axes). A regularization of 0.1 is the most effective for HbT, adequately smoothing noise but 
allowing image contrast to persist. SA requires a lower regularization of 0.01 to be most 
effective but does not reach statistical significance. 
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These data show that the HbT signal was diagnostic at a statistically significant level 
(p<0.05) for nearly the full data set when the regularization was equal to 0.1. At λ = 1, 
significance was achieved in lesions with sensitivity above 1.2%, and at λ = 0.01 significance 
was achieved in lesions with sensitivity above 3%. Regularization of λ = 0.1 was maximally 
significant above 3% tumor sensitivity (p = 0.03), but reconstructed values were not entirely 
reasonable physiologically. SA was not as good an indicator, with no λ value yielding 
statistical significance in any patient group, although λ = 0.01 was nearly significant (p = 
0.068) for lesion sensitivities above 1%. As evidenced by the differences in these results, the 
value of λ has a large effect on the entire data set as well as on individual cases. 
4. Discussion 
4.1 Sensitivity analysis 
Results in the literature indicate that NIRS imaging performance degrades as a function of 
distance from the imaging plane [34,35]. Accordingly, a measure to quantify the sensitivity of 
the measurements to the region of interest (ROI) should exist for each subject that could be 
applied prior to interpreting the data. Contrast-detail studies in NIRS imaging have also 
demonstrated that region size plays an important role in determining the minimum 
recoverable contrast [36,37]. The method described here to quantify tumor sensitivity to the 
measurement data is easy to apply and provides a quantitative metric for assessing the 
likelihood that the NIRS exam is adequately interrogating the lesion of interest. 
Although the method does not currently separate the influence of lesion size from lesion 
location, many of the ROIs in the exam series evaluated suggest that lesion location is the 
more important consideration. Further, changes in tumor radius create cubic changes in tumor 
volume whereas the Jacobian contributions change by several orders of magnitude over a 
span of centimeters. Nonetheless, understanding the effects of lesion size versus lesion 
location warrants additional investigation. 
Encoding sensitivity assessment into the exam data prior to image reconstruction provides 
a vehicle for determining which measurements have the most influence on the ROI within the 
reconstruction. This information is important because the measurement data can be noisy by 
being outside the linear range of the detector, or containing artifacts from poor fiber coupling, 
or suffer from low signal strength due to high absorption in the tissue and the sensitivity 
assessment can help distinguish noisy data from data through highly absorbing regions. 
In this study, the benign (n = 16) and malignant (n = 28) lesion groups had mean tumor 
sensitivities of 3.3% and 3.5%, respectively. However, the exam data was not significantly 
different in sensitivity between the two lesion groups indicating that the imaging technique 
was equally sensitive to the two diagnostic categories. Ensuring complete breast coverage or 
the ability to accurately target the lesion with prior knowledge of its location would improve 
the sensitivity of the optical measurements to the ROI. Many of the lesions evaluated here 
were targeted based on palpation but without the assistance of prior imaging. 
After sorting the exams by their relative lesion sensitivity, analysis of the most sensitive 
exams did not result in statistical differences between the malignant and benign groups, likely 
due to a small sample size (n<6). As the sample size increased, the confidence that the two 
groups come from different distributions increased. When tumor sensitivities greater than 
2.5% were considered, the malignant and benign groups could be distinguished with 
statistical significance in both HbT and TOI (p = 0.0037 and p = 0.00019, respectively). Both 
of these parameters remained significant at the p = 0.05 level until the relative lesion 
sensitivity fell to 1%. When exams with less than 1% sensitivity to the region of suspicion 
were included, the malignant and benign distributions became inseparable, most likely 
because the measurements were no longer adequately probing the ROI, in which case its 
influence on the measured data is lost within the normal variation of the optical 
measurements, and contrast recovery is no longer possible. 
These results suggest that diagnostically accurate data arises from cases where the lesion 
is adequately sampled, ideally with greater than 2.5% sensitivity, but with a minimum 
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sensitivity of at least 1%. Lesion sensitivity can be improved by targeting the abnormality 
based on prior knowledge of its position or with more complete coverage of the breast 
volume during NIRS data acquisition. Our single plane fiber interface allowed for targeting of 
lesions, but accurate placement was difficult in practice. Future designs of the MRI/optical 
breast coil should emphasize more complete coverage of all breast sizes. Even with 
incomplete coverage, the sensitivity parameter investigated here can be calculated 
prospectively on data where the tissue-fiber geometry and the suspected lesion geometry are 
known from the MRI scans. 
4.2 Reconstruction types 
While first introduced by Li et al, Brooksby et al, and Guven et al, prior information is known 
to improve NIRS image quantification in simulation, phantoms, and patient exams [38–41]. 
Studies have considered both spectral and spatial priors, as well as more sophisticated 
information such as water maps from simultaneous MR imaging [42–44]. While the benefits 
of incorporating prior information are well-established for NIRS imaging, when prior 
information is most effectively incorporated remains less clear [21,45,46]. Here, data was 
reconstructed using spatial and spectral priors but the spectral priors were applied at two 
different times. 
Specifically, the unconstrained spectral reconstruction method was able to statistically 
differentiate distributions of the benign and malignant tumor to adipose ratios in HbT and SA. 
Both chromophores were statistically significant when lesion sensitivity exceeded 0.5%. They 
were maximally significant when exams with lesion sensitivity above 1% were included (p = 
0.015 for HbT, p = 0.012 for SA). Although StO2, H2O, lipid, and TOI concentrations were 
also obtained, they were not diagnostically significant indicators, likely because these 
chromophores were not constrained during the reconstruction process. Only three 
wavelengths were sensitive to important spectral features of water and lipids in the current 
MRI/optical system (903, 912, and 948nm), thus, not enough spectral sensitivity was 
available to calculate these chromophores accurately after reconstruction when tumor 
sensitivity was low. Similarly to previous results, HbT and SA were good indicators of breast 
malignancy, and the unconstrained reconstruction method would be expected to produce 
promising results in a larger patient study [31,47]. 
When the constrained spectral reconstruction method was applied, HbT and TOI were the 
most significant indicators of tissue malignancy. They were maximally differentiating when 
tumor sensitivity was above 2.5% (p = 0.0037 for HbT, p = 0.00019 for TOI). Scatter 
amplitude was not significantly diagnostic (minimum p = 0.09) in this case. The constrained 
reconstruction required higher lesion sensitivity to achieve diagnostic significance in HbT and 
TOI relative to its unconstrained counterpart (2.5% vs. 1%). Although SA and HbT did not 
perform as well in the constrained case based on lesion sensitivity, they separated the 
malignant and benign group means with greater confidence when lesion sensitivity was 
greater than 1%. TOI calculated from the constrained reconstructions was the best overall 
predictor (p = 0.00019) and will continue to be an important breast tumor indicator along with 
HbT [48]. Though both algorithms are able to different malignant lesions from benign it is not 
possible to know the correct optical properties of each breast. Therefore, it can’t be said 
which algorithm is more accurate in an absolute sense and we leave that to a future 
investigation. 
4.3 Regularization parameter 
The starting value of λ produces the maximum amount of smoothing and noise suppression 
since lambda is scaled with respect to model-data mismatch. As the reconstruction is 
optimized, lambda decreases. Therefore, very noisy data requires a higher starting value to 
adequately suppress noise [27,36]. If the starting value is too high, the regularization can also 
suppress the contrast in the data. Specifically, when the regularization was set very high, 
above 1, the image contrast was significantly dampened and nearly homogeneous images 
were recovered. When the regularization was too low, under 0.01, the reconstructions became 
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unstable as the noise suppression was not sufficient and the image failed to converge to a 
physiologically valid solution. Furthermore, small changes in λ caused large changes in 
chromophore concentrations. A region of stability existed in the middle of the range, from 
0.01 to 1, where images converged to physiologically expected values and small changes in 
regularization produced small, predictable changes in the resulting images. 
While minimizing λ within the region of image stability for individual patient 
reconstructions is ideal, the same λ value was used in all reconstructions. The amount of 
regularization required varies with breast density, optical fiber placement, noise within the 
measurements, and other factors [24]. Therefore, regularization must be chosen to suppress 
noise adequately while still allowing image contrast to be recovered in most patients. For 
HbT as an example chromophore, λ = 0.1 was able to best suppress noise while allowing 
image contrast. This value achieved statistical significance in HbT for all levels of lesion 
sensitivity; however, we found it was not optimal for the other chromophores that might 
require more noise suppression such as H2O, lipids, and scatter. These latter chromophores 
favored a higher regularization, and λ = 1 was the best match for all chromophores. While this 
value yielded some unwanted smoothing in HbT, results were still diagnostically significant 
for lesion sensitivity above 1%, and favorable in the other chromophores, which benefited 
from the increased noise suppression. 
5. Conclusions 
In this study, data from breast MRI-guided near infrared spectroscopy were analyzed from a 
group of 44 breast exams delivered to patients already planned for surgery (16 benign, 28 
malignant diagnoses). Results show that optical measurement sensitivity, reconstruction 
constraints, and regularization parameter were important factors in determining the diagnostic 
significance of the MRI/optical exam. MRI/optical data was able to differentiate malignant 
from benign lesions in both HbT (p = 0.0037) and TOI (p = 0.00019), but required that 
relative spatial sensitivity in the measurements be above a 1% threshold. Lesion sensitivity 
was the most critical factor and no diagnostic significance was found when exam data with 
very low region of interest sensitivity were included in the analysis. Spectral constraints were 
required to obtain clinically diagnostic information from optical measurements of H2O, lipids, 
and TOI. The ideal regularization parameter varied case by case, and must be carefully 
selected to reduce image noise adequately, while still allowing sufficient image contrast. 
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